Matthay KK et al (2016) Neuroblastoma. Nat Rev Dis Primers 2(1):16078. https://doi.org/10.1038/nrdp.2016.78

Article  PubMed  Google Scholar 

Bosse KR, Maris JM (2016) Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122(1):20–33. https://doi.org/10.1002/cncr.29706

Article  PubMed  Google Scholar 

Kumar P, Soni A, Tomar V, Singh T, Nemiwal M (2024) Greener and sustainable fabrication of DNA/RNA base-pair conjugates by [CuO[HN(C2H5)3[Al2Cl7] nanocatalyst: emerging drug against prostate cancer. Sustain Chem Pharm 41:101714. https://doi.org/10.1016/j.scp.2024.101714

Article  Google Scholar 

Padovan-Merhar OM et al (2016) Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLoS Genet 12(12):e1006501. https://doi.org/10.1371/journal.pgen.1006501

Article  PubMed  PubMed Central  Google Scholar 

Kholodenko IV, Kalinovsky DV, Doronin II, Deyev SM, Kholodenko RV (2018) Neuroblastoma origin and therapeutic targets for immunotherapy. J Immunol Res 2018:1–25. https://doi.org/10.1155/2018/7394268

Article  Google Scholar 

Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE (2017) Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 17(4):369–386. https://doi.org/10.1080/14737140.2017.1285230

Article  PubMed  Google Scholar 

Perri P, Ponzoni M, Corrias MV, Ceccherini I, Candiani S, Bachetti T (2021) A focus on regulatory networks linking MicroRNAs, transcription factors and target genes in neuroblastoma. Cancers (Basel) 13(21):5528. https://doi.org/10.3390/cancers13215528

Article  PubMed  Google Scholar 

Ladenstein R et al (2018) Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1617–1629. https://doi.org/10.1016/S1470-2045(18)30578-3

Article  PubMed  Google Scholar 

Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202–2211. https://doi.org/10.1056/NEJMra0804577

Article  PubMed  PubMed Central  Google Scholar 

Newman EA et al (2019) Update on neuroblastoma. J Pediatr Surg 54(3):383–389. https://doi.org/10.1016/j.jpedsurg.2018.09.004

Article  PubMed  Google Scholar 

Wang J-X et al (2022) Prognostic impact of tumor size on patients with neuroblastoma in a SEER-based study. Cancer Med 11(14):2779–2789. https://doi.org/10.1002/cam4.4653

Article  PubMed  PubMed Central  Google Scholar 

Salemi F et al (2022) Neuroblastoma: essential genetic pathways and current therapeutic options. Eur J Pharmacol 926:175030. https://doi.org/10.1016/j.ejphar.2022.175030

Article  PubMed  Google Scholar 

Rha SE, Byun JY, Jung SE, Chun HJ, Lee HG, Lee JM (2003) Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics 23(1):29–43. https://doi.org/10.1148/rg.231025050

Article  PubMed  Google Scholar 

Louis CU, Shohet JM (2015) Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 66(1):49–63. https://doi.org/10.1146/annurev-med-011514-023121

Article  PubMed  Google Scholar 

S. Mahapatra and K. B. Challagundla, Neuroblastoma. 2023.

M. Beals, B. Ramoo, C. Clinton Frazee, and U. Garg, Quantitation of neuroblastoma markers homovanillic acid (HVA) and vanillylmandelic acid (VMA) in urine by gas chromatography–mass spectrometry (GC/MS), 2022, pp. 185–194. https://doi.org/10.1007/978-1-0716-2565-1_17.

Blavier L, Yang R-M, DeClerck YA (2020) The tumor microenvironment in neuroblastoma: new players, new mechanisms of interaction and new perspectives. Cancers (Basel) 12(10):2912. https://doi.org/10.3390/cancers12102912

Article  PubMed  Google Scholar 

Bernards R, Dessain SK, Weinberg RA (1986) N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47(5):667–674. https://doi.org/10.1016/0092-8674(86)90509-X

Article  PubMed  Google Scholar 

HaDuong JH et al (2015) Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. Int J Cancer 137(4):797–809. https://doi.org/10.1002/ijc.29465

Article  PubMed  PubMed Central  Google Scholar 

Matthay KK et al (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078. https://doi.org/10.1038/nrdp.2016.78

Article  PubMed  Google Scholar 

R. E. George et al., Activating mutations in ALK provide a therapeutic target in neuroblastoma., Nature, vol. 455, no. 7215, pp. 975–8, 2008, https://doi.org/10.1038/nature07397.

Bourdeaut F et al (2005) Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett 228(1–2):51–58. https://doi.org/10.1016/j.canlet.2005.01.055

Article  PubMed  Google Scholar 

Trochet D et al (2004) Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74(4):761–764. https://doi.org/10.1086/383253

Article  PubMed  PubMed Central  Google Scholar 

van Limpt V et al (2004) The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23(57):9280–9288. https://doi.org/10.1038/sj.onc.1208157

Article  PubMed  Google Scholar 

van Limpt V, Chan A, Schramm A, Eggert A, Versteeg R (2005) Phox2B mutations and the Delta-Notch pathway in neuroblastoma. Cancer Lett 228(1–2):59–63. https://doi.org/10.1016/j.canlet.2005.02.050

Article  PubMed  Google Scholar 

Pugh TJ et al (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet 45(3):279–284. https://doi.org/10.1038/ng.2529

Article  PubMed  PubMed Central  Google Scholar 

Valentijn LJ et al (2015) TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 47(12):1411–1414. https://doi.org/10.1038/ng.3438

Article  PubMed  Google Scholar 

Ackermann S et al (2018) A mechanistic classification of clinical phenotypes in neuroblastoma. Science 362(6419):1165–1170. https://doi.org/10.1126/science.aat6768

Article  PubMed  PubMed Central  Google Scholar 

Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M (1998) Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 16(10):3286–3294. https://doi.org/10.1200/JCO.1998.16.10.3286

Article  PubMed  Google Scholar 

Mackenbach JP et al (2018) Trends in health inequalities in 27 European countries. Proc Natl Acad Sci U S A 115(25):6440–6445. https://doi.org/10.1073/pnas.1800028115

Article  PubMed  PubMed Central  Google Scholar 

Zeid R et al (2018) Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nat Genet 50(4):515–523. https://doi.org/10.1038/s41588-018-0044-9

Article  PubMed  PubMed Central  Google Scholar 

Westermann F et al (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9(10):R150. https://doi.org/10.1186/gb-2008-9-10-r150

Article  PubMed  PubMed Central  Google Scholar 

Longo L et al (2008) PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. Int J Oncol 33(5):985–991

PubMed  Google Scholar 

Raabe EH et al (2008) Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 27(4):469–476. https://doi.org/10.1038/sj.onc.1210659

Article  PubMed  Google Scholar 

Molenaar JJ et al (2012) LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet 44(11):1199–1206. https://doi.org/10.1038/ng.2436

Article